USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
BIOASSAY SYSTEMS, LLC
Address:
3423 INVESTMENT BLVD, STE 11
HAYWARD, CA 94545-
Phone:
N/A
URL:
N/A
EIN:
830377490
DUNS:
174630215
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $705,495.00 6
SBIR Phase II $999,913.00 1

Award List:

PRODUCING ERYTHROPOIETIN FROM HUMAN KIDNEY CELLS IN CULTURE.

Award Year / Program / Phase:
1983 / SBIR / Phase I
Award Amount:
$45,608.00
Agency:
HHS
Principal Investigator:
Mark p. bear , PRINCIPAL INVESTIGATOR
Abstract:
Producing erythropoietin from human kidney cells in culture.at present, the only commercially available source of human erythropoietin is from the urine of aplastic anemics. humancells in culture represents an excellent alternative source for human erythropoietin. if erythropoietin can be… More

THE PURPOSE OF THIS PHASE I PROPOSAL IS TO DEVELOP A MAMMALIAN CELL CULTURE ANEUPLOIDY ASSAY USING THE CAK MOUSE CELL LINE.

Award Year / Program / Phase:
1983 / SBIR / Phase I
Award Amount:
$60,102.00
Agency:
HHS
Principal Investigator:
Kenneth s. loveday ph.d. , PRINCIPAL INVESTIGATOR
Abstract:
The purpose of this phase i proposal is to develop a mammalian cell culture aneuploidy assay using the cak mouse cell line. while a great number of short term assays have been developed to detect compounds which induce either gene mutations or chromosomal damage, little research has focusedon the… More

SBIR TOPIC 229 A ROBUST AND RIGOROUS PHARMACODYNAMIC ASSAY FOR AKT

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$149,947.00
Agency:
HHS
Principal Investigator:
Shugui Frank
Abstract:
N/a

SBIR TOPIC 229 A ROBUST AND RIGOROUS PHARMACODYNAMIC ASSAY FOR PTP1B

Award Year / Program / Phase:
2007 / SBIR / Phase I
Award Amount:
$149,856.00
Agency:
HHS
Principal Investigator:
Shugui Frank
Abstract:
N/a

TOPIC 229: PHASE I ERK DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYS

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$149,987.00
Agency:
HHS
Principal Investigator:
Frank Huang
Abstract:
Extracellular-signal-regulated kinase (ERK) is a key protein kinase of the MAP kinase pathway and plays a key role in cell proliferation, differentiation and migration. The MAPK cascade presents many targets for the development of novel and safer cancer th erapies. Despite a lot of progress in the… More

TOPIC 229: PHASE I AMPK DEV. OF MOLECULAR PHARMACODYNAMIC ASSAYS

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$149,995.00
Agency:
HHS
Principal Investigator:
Frank Huang
Abstract:
AMP-activated protein kinase (AMPK) is a serine/threonine kinase that is a member of a metabolite sensing protein kinase family. AMPK is involved in controlling cellular metabolism and cell proliferation and when activated has been found to be a potent tum or suppressor. Despite a lot of progress in… More

Not Available

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$999,913.00
Agency:
HHS
Principal Investigator:
Frank Huang
Abstract:
The Contractor will develop pharmacodynamic assays for measuring a number of high-priority molecular targets. These assays will be suitable for pre-clinical and clinical testing to allow for rapid evaluation of treatment responses, gauge treatment correspondence to tumor stasis/regression, allow… More